Insider trading is the trading of a company’s securities by individuals with access to confidential or material non-public information about the company.
A company is required to report trading by corporate officers, directors, or other company members with significant access to privileged information to the Securities and Exchange Commission (SEC).
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Nurix Therapeutics Inc | Christine Ring | Chief Legal Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 02 Sep 2026 | 5,787 | 117,037 | - | - | Employee Stock Option (right to buy) | |
| Nurix Therapeutics Inc | Christine Ring | Chief Legal Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 8.72 per share. | 02 Sep 2026 | 5,787 | 14,897 | - | 8.7 | 50,463 | Common Stock |
| Nurix Therapeutics Inc | Christine Ring | Chief Legal Officer | Sale of securities on an exchange or to another person at price $ 25.69 per share. | 02 Sep 2026 | 5,387 | 9,510 | - | 25.7 | 138,417 | Common Stock |
| Nurix Therapeutics Inc | Christine Ring | Chief Legal Officer | Sale of securities on an exchange or to another person at price $ 26.64 per share. | 02 Sep 2026 | 400 | 9,110 | - | 26.6 | 10,655 | Common Stock |
| ARS Pharma Inc | Margaret Ekins Smith | Chief Commercial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Sep 2026 | 1,001,738 | 1,001,738 | - | - | Stock Option (right to buy) | |
| Outlook Therapeutics Inc | Kevin Lundquist | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Sep 2026 | 500,000 | 500,000 | - | - | Employee Stock Option (Right to Buy) | |
| Crinetics Pharma Inc | R. Scott Struthers | Director, President & CEO | Sale or transfer of securities back to the company at price $ 0.00 per share. | 01 Sep 2026 | 313,000 | 0 | - | - | Stock Option (Right to Buy) | |
| Crinetics Pharma Inc | R. Scott Struthers | Director, President & CEO | Sale or transfer of securities back to the company at price $ 0.00 per share. | 01 Sep 2026 | 287,700 | 0 | - | - | Stock Option (Right to Buy) | |
| Aura Biosciences Inc | Susan Abu-Absi | Chief Operating Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Sep 2026 | 265,487 | 265,487 | - | - | Stock Option (Right to Buy) | |
| Crinetics Pharma Inc | R. Scott Struthers | Director, President & CEO | Sale or transfer of securities back to the company at price $ 0.00 per share. | 01 Sep 2026 | 259,058 | 0 | - | - | Stock Option (Right to Buy) | |
| Crinetics Pharma Inc | R. Scott Struthers | Director, President & CEO | Sale or transfer of securities back to the company at price $ 85.00 per share. | 01 Sep 2026 | 248,043 | 176,663 (0%) | 1% | 85 | 21,083,655 | Common Stock |
| Crinetics Pharma Inc | R. Scott Struthers | Director, President & CEO | Sale or transfer of securities back to the company at price $ 0.00 per share. | 01 Sep 2026 | 244,205 | 0 | - | - | Stock Option (Right to Buy) | |
| Crinetics Pharma Inc | R. Scott Struthers | Director, President & CEO | Sale or transfer of securities back to the company at price $ 0.00 per share. | 01 Sep 2026 | 240,000 | 0 | - | - | Stock Option (Right to Buy) | |
| Crinetics Pharma Inc | R. Scott Struthers | Director, President & CEO | Sale or transfer of securities back to the company at price $ 0.00 per share. | 01 Sep 2026 | 228,000 | 0 | - | - | Stock Option (Right to Buy) | |
| Aura Biosciences Inc | Erica Kratz | Chief Reg. & Quality Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Sep 2026 | 199,115 | 199,115 | - | - | Stock Option (Right to Buy) | |
| Crinetics Pharma Inc | R. Scott Struthers | Director, President & CEO | Sale or transfer of securities back to the company at price $ 0.00 per share. | 01 Sep 2026 | 195,578 | 0 | - | - | Stock Option (Right to Buy) | |
| Crinetics Pharma Inc | R. Scott Struthers | Director, President & CEO | Sale or transfer of securities back to the company at price $ 85.00 per share. | 01 Sep 2026 | 176,663 | 0 (0%) | 0% | 85 | 15,016,355 | Common Stock |
| Crinetics Pharma Inc | R. Scott Struthers | Director, President & CEO | Sale or transfer of securities back to the company at price $ 0.00 per share. | 01 Sep 2026 | 172,281 | 0 | - | - | Stock Option (Right to Buy) | |
| Crinetics Pharma Inc | R. Scott Struthers | Director, President & CEO | Sale or transfer of securities back to the company at price $ 85.00 per share. | 01 Sep 2026 | 136,805 | 0 (0%) | 0% | 85 | 11,628,425 | Common Stock |
| Aura Biosciences Inc | Susan Abu-Absi | Chief Operating Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Sep 2026 | 134,513 | 134,513 | - | 0 | Common Stock | |
| Aura Biosciences Inc | Janet Jill Hopkins | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Sep 2026 | 116,150 | 116,150 | - | - | Stock Option (Right to Buy) | |
| Crinetics Pharma Inc | Wendell D. Wierenga | Director | Sale or transfer of securities back to the company at price $ 85.00 per share. | 01 Sep 2026 | 116,146 | 5,925 (0%) | 0% | 85 | 9,872,410 | Common Stock |
| Crinetics Pharma Inc | R. Scott Struthers | Director, President & CEO | Sale or transfer of securities back to the company at price $ 85.00 per share. | 01 Sep 2026 | 111,100 | 0 (0%) | 0% | 85 | 9,443,500 | Common Stock |
| Crinetics Pharma Inc | R. Scott Struthers | Director, President & CEO | Sale or transfer of securities back to the company at price $ 85.00 per share. | 01 Sep 2026 | 111,100 | 0 (0%) | 0% | 85 | 9,443,500 | Common Stock |
| Crinetics Pharma Inc | R. Scott Struthers | Director, President & CEO | Sale or transfer of securities back to the company at price $ 85.00 per share. | 01 Sep 2026 | 111,100 | 0 (0%) | 0% | 85 | 9,443,500 | Common Stock |
| Crinetics Pharma Inc | R. Scott Struthers | Director, President & CEO | Sale or transfer of securities back to the company at price $ 85.00 per share. | 01 Sep 2026 | 111,100 | 0 (0%) | 0% | 85 | 9,443,500 | Common Stock |
| Crinetics Pharma Inc | R. Scott Struthers | Director, President & CEO | Sale or transfer of securities back to the company at price $ 85.00 per share. | 01 Sep 2026 | 110,000 | 0 (0%) | 0% | 85 | 9,350,000 | Common Stock |
| Crinetics Pharma Inc | Stephen F. Betz | Chief Scientific Officer | Sale or transfer of securities back to the company at price $ 0.00 per share. | 01 Sep 2026 | 110,000 | 0 | - | - | Stock Option (Right to Buy) | |
| Crinetics Pharma Inc | R. Scott Struthers | Director, President & CEO | Sale or transfer of securities back to the company at price $ 85.00 per share. | 01 Sep 2026 | 106,000 | 0 (0%) | 0% | 85 | 9,010,000 | Common Stock |
| Aura Biosciences Inc | Erica Kratz | Chief Reg. & Quality Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Sep 2026 | 100,885 | 100,885 | - | 0 | Common Stock | |
| Crinetics Pharma Inc | R. Scott Struthers | Director, President & CEO | Sale or transfer of securities back to the company at price $ 85.00 per share. | 01 Sep 2026 | 100,000 | 0 (0%) | 0% | 85 | 8,500,000 | Common Stock |
| Crinetics Pharma Inc | Isabel Kalofonos | Chief Commercial Officer | Sale or transfer of securities back to the company at price $ 0.00 per share. | 01 Sep 2026 | 97,500 | 0 | - | - | Stock Option (Right to Buy) | |
| Crinetics Pharma Inc | Stephen F. Betz | Chief Scientific Officer | Sale or transfer of securities back to the company at price $ 0.00 per share. | 01 Sep 2026 | 90,514 | 0 | - | - | Stock Option (Right to Buy) | |
| Crinetics Pharma Inc | Stephen F. Betz | Chief Scientific Officer | Sale or transfer of securities back to the company at price $ 0.00 per share. | 01 Sep 2026 | 87,000 | 0 | - | - | Stock Option (Right to Buy) | |
| Crinetics Pharma Inc | Stephen F. Betz | Chief Scientific Officer | Sale or transfer of securities back to the company at price $ 0.00 per share. | 01 Sep 2026 | 85,000 | 0 | - | - | Stock Option (Right to Buy) | |
| Crinetics Pharma Inc | Tobin C. Schilke | Chief Financial & Infra. Ofcr. | Sale or transfer of securities back to the company at price $ 0.00 per share. | 01 Sep 2026 | 80,000 | 0 | - | - | Stock Option (Right to Buy) | |
| Crinetics Pharma Inc | R. Scott Struthers | Director, President & CEO | Sale or transfer of securities back to the company at price $ 85.00 per share. | 01 Sep 2026 | 80,000 | 0 (0%) | 0% | 85 | 6,800,000 | Common Stock |
| Amneal Pharma Inc (Class A) | Andrew S. Boyer | Executive Vice President | Gift of securities by or to the insider at price $ 0.00 per share. | 01 Sep 2026 | 80,000 | 193,646 (0%) | 0% | 0 | Class A Common Stock | |
| Crinetics Pharma Inc | Stephen F. Betz | Chief Scientific Officer | Sale or transfer of securities back to the company at price $ 85.00 per share. | 01 Sep 2026 | 79,650 | 0 (0%) | 0% | 85 | 6,770,250 | Common Stock |
| Crinetics Pharma Inc | Stephen F. Betz | Chief Scientific Officer | Sale or transfer of securities back to the company at price $ 0.00 per share. | 01 Sep 2026 | 77,000 | 0 | - | - | Stock Option (Right to Buy) | |
| Oruka Therapeutics Inc | Lawrence Otto Klein | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 7.80 per share. | 01 Sep 2026 | 75,000 | 1,000,580 | - | 7.8 | 585,000 | Common Stock |
| Oruka Therapeutics Inc | Lawrence Otto Klein | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Sep 2026 | 75,000 | 1,553,513 | - | - | Employee Warrant (right to buy) | |
| Crinetics Pharma Inc | Stephen F. Betz | Chief Scientific Officer | Sale or transfer of securities back to the company at price $ 0.00 per share. | 01 Sep 2026 | 74,540 | 0 | - | - | Stock Option (Right to Buy) | |
| Crinetics Pharma Inc | Tobin C. Schilke | Chief Financial & Infra. Ofcr. | Sale or transfer of securities back to the company at price $ 85.00 per share. | 01 Sep 2026 | 71,471 | 0 (0%) | 0% | 85 | 6,075,035 | Common Stock |
| Crinetics Pharma Inc | Stephen F. Betz | Chief Scientific Officer | Sale or transfer of securities back to the company at price $ 0.00 per share. | 01 Sep 2026 | 65,000 | 0 | - | - | Stock Option (Right to Buy) | |
| Oruka Therapeutics Inc | Lawrence Otto Klein | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 91.90 per share. | 01 Sep 2026 | 63,596 | 930,380 | - | 91.9 | 5,844,237 | Common Stock |
| Crinetics Pharma Inc | Stephen F. Betz | Chief Scientific Officer | Sale or transfer of securities back to the company at price $ 0.00 per share. | 01 Sep 2026 | 60,000 | 0 | - | - | Stock Option (Right to Buy) | |
| Aura Biosciences Inc | Janet Jill Hopkins | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Sep 2026 | 58,850 | 380,190 | - | 0 | Common Stock | |
| Crinetics Pharma Inc | Stephen F. Betz | Chief Scientific Officer | Sale or transfer of securities back to the company at price $ 85.00 per share. | 01 Sep 2026 | 58,286 | 79,650 (0%) | 0% | 85 | 4,954,310 | Common Stock |
| Crinetics Pharma Inc | Stephen F. Betz | Chief Scientific Officer | Sale or transfer of securities back to the company at price $ 0.00 per share. | 01 Sep 2026 | 56,250 | 0 | - | - | Stock Option (Right to Buy) | |
| Crinetics Pharma Inc | Isabel Kalofonos | Chief Commercial Officer | Sale or transfer of securities back to the company at price $ 0.00 per share. | 01 Sep 2026 | 55,000 | 0 | - | - | Stock Option (Right to Buy) | |
| Crinetics Pharma Inc | Tobin C. Schilke | Chief Financial & Infra. Ofcr. | Sale or transfer of securities back to the company at price $ 0.00 per share. | 01 Sep 2026 | 50,000 | 0 | - | - | Stock Option (Right to Buy) | |
| Crinetics Pharma Inc | Stephen F. Betz | Chief Scientific Officer | Sale or transfer of securities back to the company at price $ 0.00 per share. | 01 Sep 2026 | 47,000 | 0 | - | - | Stock Option (Right to Buy) | |
| Aura Biosciences Inc | Amy Elazzouzi | SVP, Finance & PAO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Sep 2026 | 46,460 | 46,460 | - | - | Stock Option (Right to Buy) | |
| Zenas Biopharma Inc | Christy J. Oliger | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Sep 2026 | 37,000 | 37,000 | - | - | Stock Option (Right to Buy) | |
| Crinetics Pharma Inc | Rogerio Vivaldi Coelho | Director | Sale or transfer of securities back to the company at price $ 0.00 per share. | 01 Sep 2026 | 35,000 | 0 | - | - | Stock Option (Right to Buy) | |
| Crinetics Pharma Inc | Caren Deardorf | Director | Sale or transfer of securities back to the company at price $ 0.00 per share. | 01 Sep 2026 | 35,000 | 0 | - | - | Stock Option (Right to Buy) | |
| Crinetics Pharma Inc | Isabel Kalofonos | Chief Commercial Officer | Sale or transfer of securities back to the company at price $ 85.00 per share. | 01 Sep 2026 | 34,000 | 0 (0%) | 0% | 85 | 2,890,000 | Common Stock |
| Recursion Pharma Inc (Class A) | Blake Borgeson | Director | Sale of securities on an exchange or to another person at price $ 3.34 per share. | 01 Sep 2026 | 30,000 | 6,158,287 | - | 3.3 | 100,200 | Class A Common Stock |
| Crinetics Pharma Inc | Camille L. Bedrosian | Director | Sale or transfer of securities back to the company at price $ 0.00 per share. | 01 Sep 2026 | 25,000 | 0 | - | - | Stock Option (Right to Buy) | |
| Crinetics Pharma Inc | Stephanie S. Okey | Director | Sale or transfer of securities back to the company at price $ 0.00 per share. | 01 Sep 2026 | 25,000 | 0 | - | - | Stock Option (Right to Buy) | |
| Aura Biosciences Inc | Amy Elazzouzi | SVP, Finance & PAO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Sep 2026 | 23,540 | 143,600 | - | 0 | Common Stock | |
| Crinetics Pharma Inc | Matthew K. Fust | Director | Sale or transfer of securities back to the company at price $ 85.00 per share. | 01 Sep 2026 | 22,836 | 5,925 (0%) | 0% | 85 | 1,941,060 | Common Stock |
| Structure Therapeutics Inc (ADR) | Xichen Lin | CHIEF SCIENTIFIC OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.34 per share. | 01 Sep 2026 | 17,817 | 246,777 | - | 0.3 | 6,058 | Ordinary Shares |
| Structure Therapeutics Inc (ADR) | Xichen Lin | CHIEF SCIENTIFIC OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Sep 2026 | 17,817 | 125,081 | - | - | Share Option (right to buy) | |
| Structure Therapeutics Inc (ADR) | Xichen Lin | CHIEF SCIENTIFIC OFFICER | 01 Sep 2026 | 17,817 | 228,960 | - | 0 | Ordinary Shares | ||
| Crinetics Pharma Inc | Matthew K. Fust | Director | Sale or transfer of securities back to the company at price $ 0.00 per share. | 01 Sep 2026 | 17,500 | 0 | - | - | Stock Option (Right to Buy) | |
| Crinetics Pharma Inc | Wendell D. Wierenga | Director | Sale or transfer of securities back to the company at price $ 0.00 per share. | 01 Sep 2026 | 17,500 | 0 | - | - | Stock Option (Right to Buy) | |
| Crinetics Pharma Inc | Wendell D. Wierenga | Director | Sale or transfer of securities back to the company at price $ 0.00 per share. | 01 Sep 2026 | 17,500 | 0 | - | - | Stock Option (Right to Buy) | |
| Crinetics Pharma Inc | Wendell D. Wierenga | Director | Sale or transfer of securities back to the company at price $ 0.00 per share. | 01 Sep 2026 | 17,500 | 0 | - | - | Stock Option (Right to Buy) | |
| Crinetics Pharma Inc | Camille L. Bedrosian | Director | Sale or transfer of securities back to the company at price $ 0.00 per share. | 01 Sep 2026 | 17,500 | 0 | - | - | Stock Option (Right to Buy) | |
| Crinetics Pharma Inc | Camille L. Bedrosian | Director | Sale or transfer of securities back to the company at price $ 0.00 per share. | 01 Sep 2026 | 17,500 | 0 | - | - | Stock Option (Right to Buy) | |
| Crinetics Pharma Inc | Camille L. Bedrosian | Director | Sale or transfer of securities back to the company at price $ 0.00 per share. | 01 Sep 2026 | 17,500 | 0 | - | - | Stock Option (Right to Buy) | |
| Crinetics Pharma Inc | Rogerio Vivaldi Coelho | Director | Sale or transfer of securities back to the company at price $ 0.00 per share. | 01 Sep 2026 | 17,500 | 0 | - | - | Stock Option (Right to Buy) | |
| Crinetics Pharma Inc | Stephanie S. Okey | Director | Sale or transfer of securities back to the company at price $ 0.00 per share. | 01 Sep 2026 | 17,500 | 0 | - | - | Stock Option (Right to Buy) | |
| Crinetics Pharma Inc | Stephanie S. Okey | Director | Sale or transfer of securities back to the company at price $ 0.00 per share. | 01 Sep 2026 | 17,500 | 0 | - | - | Stock Option (Right to Buy) | |
| Crinetics Pharma Inc | Weston Nichols | Director | Sale or transfer of securities back to the company at price $ 0.00 per share. | 01 Sep 2026 | 17,500 | 0 | - | - | Stock Option (Right to Buy) | |
| Crinetics Pharma Inc | Weston Nichols | Director | Sale or transfer of securities back to the company at price $ 0.00 per share. | 01 Sep 2026 | 17,500 | 0 | - | - | Stock Option (Right to Buy) | |
| Crinetics Pharma Inc | Weston Nichols | Director | Sale or transfer of securities back to the company at price $ 0.00 per share. | 01 Sep 2026 | 17,500 | 0 | - | - | Stock Option (Right to Buy) | |
| Crinetics Pharma Inc | Caren Deardorf | Director | Sale or transfer of securities back to the company at price $ 0.00 per share. | 01 Sep 2026 | 17,500 | 0 | - | - | Stock Option (Right to Buy) | |
| Xeris Biopharma Holdings Inc | Beth P. Hecht | See Remarks | Sale of securities on an exchange or to another person at price $ 8.49 per share. | 01 Sep 2026 | 16,666 | 1,127,796 (4%) | 0% | 8.5 | 141,434 | Common Stock |
| Crinetics Pharma Inc | Camille L. Bedrosian | Director | Sale or transfer of securities back to the company at price $ 85.00 per share. | 01 Sep 2026 | 16,300 | 5,925 (0%) | 0% | 85 | 1,385,500 | Common Stock |
| Crinetics Pharma Inc | Weston Nichols | Director | Sale or transfer of securities back to the company at price $ 85.00 per share. | 01 Sep 2026 | 16,300 | 5,925 (0%) | 0% | 85 | 1,385,500 | Common Stock |
| Crinetics Pharma Inc | Caren Deardorf | Director | Sale or transfer of securities back to the company at price $ 85.00 per share. | 01 Sep 2026 | 16,300 | 5,925 (0%) | 0% | 85 | 1,385,500 | Common Stock |
| Abeona Therapeutics Inc | Mark J. Alvino | Director | Sale of securities on an exchange or to another person at price $ 5.86 per share. | 01 Sep 2026 | 15,000 | 62,065 (0%) | 0% | 5.9 | 87,966 | Common Stock |
| Xeris Biopharma Holdings Inc | Kevin McCulloch | See Remarks | Sale of securities on an exchange or to another person at price $ 8.49 per share. | 01 Sep 2026 | 15,000 | 1,639,208 (6%) | 0% | 8.5 | 127,308 | Common Stock |
| Crinetics Pharma Inc | Stephen F. Betz | Chief Scientific Officer | Sale or transfer of securities back to the company at price $ 0.00 per share. | 01 Sep 2026 | 15,000 | 0 | - | - | Stock Option (Right to Buy) | |
| Crinetics Pharma Inc | Rogerio Vivaldi Coelho | Director | Sale or transfer of securities back to the company at price $ 85.00 per share. | 01 Sep 2026 | 13,300 | 5,925 (0%) | 0% | 85 | 1,130,500 | Common Stock |
| Crinetics Pharma Inc | Matthew K. Fust | Director | Sale or transfer of securities back to the company at price $ 0.00 per share. | 01 Sep 2026 | 12,500 | 0 | - | - | Stock Option (Right to Buy) | |
| Crinetics Pharma Inc | Wendell D. Wierenga | Director | Sale or transfer of securities back to the company at price $ 0.00 per share. | 01 Sep 2026 | 12,500 | 0 | - | - | Stock Option (Right to Buy) | |
| Crinetics Pharma Inc | Wendell D. Wierenga | Director | Sale or transfer of securities back to the company at price $ 0.00 per share. | 01 Sep 2026 | 12,500 | 0 | - | - | Stock Option (Right to Buy) | |
| Crinetics Pharma Inc | Wendell D. Wierenga | Director | Sale or transfer of securities back to the company at price $ 0.00 per share. | 01 Sep 2026 | 12,500 | 0 | - | - | Stock Option (Right to Buy) | |
| Crinetics Pharma Inc | Camille L. Bedrosian | Director | Sale or transfer of securities back to the company at price $ 0.00 per share. | 01 Sep 2026 | 12,500 | 0 | - | - | Stock Option (Right to Buy) | |
| Crinetics Pharma Inc | Rogerio Vivaldi Coelho | Director | Sale or transfer of securities back to the company at price $ 0.00 per share. | 01 Sep 2026 | 12,500 | 0 | - | - | Stock Option (Right to Buy) | |
| Crinetics Pharma Inc | Stephanie S. Okey | Director | Sale or transfer of securities back to the company at price $ 0.00 per share. | 01 Sep 2026 | 12,500 | 0 | - | - | Stock Option (Right to Buy) | |
| Crinetics Pharma Inc | Stephanie S. Okey | Director | Sale or transfer of securities back to the company at price $ 0.00 per share. | 01 Sep 2026 | 12,500 | 0 | - | - | Stock Option (Right to Buy) | |
| Crinetics Pharma Inc | Weston Nichols | Director | Sale or transfer of securities back to the company at price $ 0.00 per share. | 01 Sep 2026 | 12,500 | 0 | - | - | Stock Option (Right to Buy) | |
| Crinetics Pharma Inc | Weston Nichols | Director | Sale or transfer of securities back to the company at price $ 0.00 per share. | 01 Sep 2026 | 12,500 | 0 | - | - | Stock Option (Right to Buy) | |
| Crinetics Pharma Inc | Weston Nichols | Director | Sale or transfer of securities back to the company at price $ 0.00 per share. | 01 Sep 2026 | 12,500 | 0 | - | - | Stock Option (Right to Buy) | |
| Crinetics Pharma Inc | Caren Deardorf | Director | Sale or transfer of securities back to the company at price $ 0.00 per share. | 01 Sep 2026 | 12,500 | 0 | - | - | Stock Option (Right to Buy) | |
| Crinetics Pharma Inc | Matthew K. Fust | Director | Sale or transfer of securities back to the company at price $ 0.00 per share. | 01 Sep 2026 | 10,350 | 0 | - | - | Stock Option (Right to Buy) | |
| Crinetics Pharma Inc | Wendell D. Wierenga | Director | Sale or transfer of securities back to the company at price $ 0.00 per share. | 01 Sep 2026 | 10,350 | 0 | - | - | Stock Option (Right to Buy) | |
| Crinetics Pharma Inc | Camille L. Bedrosian | Director | Sale or transfer of securities back to the company at price $ 0.00 per share. | 01 Sep 2026 | 10,350 | 0 | - | - | Stock Option (Right to Buy) | |
| Crinetics Pharma Inc | Rogerio Vivaldi Coelho | Director | Sale or transfer of securities back to the company at price $ 0.00 per share. | 01 Sep 2026 | 10,350 | 0 | - | - | Stock Option (Right to Buy) | |
| Crinetics Pharma Inc | Stephanie S. Okey | Director | Sale or transfer of securities back to the company at price $ 0.00 per share. | 01 Sep 2026 | 10,350 | 0 | - | - | Stock Option (Right to Buy) | |
| Crinetics Pharma Inc | Weston Nichols | Director | Sale or transfer of securities back to the company at price $ 0.00 per share. | 01 Sep 2026 | 10,350 | 0 | - | - | Stock Option (Right to Buy) | |
| Crinetics Pharma Inc | Caren Deardorf | Director | Sale or transfer of securities back to the company at price $ 0.00 per share. | 01 Sep 2026 | 10,350 | 0 | - | - | Stock Option (Right to Buy) | |
| Crinetics Pharma Inc | Matthew K. Fust | Director | Sale or transfer of securities back to the company at price $ 0.00 per share. | 01 Sep 2026 | 9,730 | 0 | - | - | Stock Option (Right to Buy) | |
| Crinetics Pharma Inc | Wendell D. Wierenga | Director | Sale or transfer of securities back to the company at price $ 0.00 per share. | 01 Sep 2026 | 9,730 | 0 | - | - | Stock Option (Right to Buy) | |
| Crinetics Pharma Inc | Camille L. Bedrosian | Director | Sale or transfer of securities back to the company at price $ 0.00 per share. | 01 Sep 2026 | 9,730 | 0 | - | - | Stock Option (Right to Buy) | |
| Crinetics Pharma Inc | Rogerio Vivaldi Coelho | Director | Sale or transfer of securities back to the company at price $ 0.00 per share. | 01 Sep 2026 | 9,730 | 0 | - | - | Stock Option (Right to Buy) | |
| Crinetics Pharma Inc | Stephanie S. Okey | Director | Sale or transfer of securities back to the company at price $ 0.00 per share. | 01 Sep 2026 | 9,730 | 0 | - | - | Stock Option (Right to Buy) | |
| Crinetics Pharma Inc | Weston Nichols | Director | Sale or transfer of securities back to the company at price $ 0.00 per share. | 01 Sep 2026 | 9,730 | 0 | - | - | Stock Option (Right to Buy) | |
| Crinetics Pharma Inc | Caren Deardorf | Director | Sale or transfer of securities back to the company at price $ 0.00 per share. | 01 Sep 2026 | 9,730 | 0 | - | - | Stock Option (Right to Buy) | |
| United Therapeutics Corp | Martine A. Rothblatt | Director, Chairperson & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Sep 2026 | 9,500 | 18,410 | - | - | Stock Option | |
| United Therapeutics Corp | Martine A. Rothblatt | Director, Chairperson & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 135.42 per share. | 01 Sep 2026 | 9,500 | 333,943 (0%) | 0% | 135.4 | 1,286,490 | Common Stock |
| Alkermes PLC | Craig C. Hopkinson | EVP R&D, Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 46.99 per share. | 01 Sep 2026 | 9,000 | 65,389 (0%) | 0% | 47.0 | 422,874 | Ordinary Shares |
| Crinetics Pharma Inc | Rogerio Vivaldi Coelho | Director | Sale or transfer of securities back to the company at price $ 0.00 per share. | 01 Sep 2026 | 8,750 | 0 | - | - | Stock Option (Right to Buy) | |
| Gilead Sciences | Daniel P. O'Day | Director, Chairman & CEO | Sale of securities on an exchange or to another person at price $ 148.36 per share. | 01 Sep 2026 | 7,992 | 582,541 (0%) | 0% | 148.4 | 1,185,722 | Common Stock |
| Crinetics Pharma Inc | Tobin C. Schilke | Chief Financial & Infra. Ofcr. | Sale or transfer of securities back to the company at price $ 85.00 per share. | 01 Sep 2026 | 7,956 | 71,471 (0%) | 0% | 85 | 676,260 | Common Stock |
| Oruka Therapeutics Inc | Lawrence Otto Klein | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 90.79 per share. | 01 Sep 2026 | 6,604 | 993,976 | - | 90.8 | 599,556 | Common Stock |
| Crinetics Pharma Inc | Stephanie S. Okey | Director | Sale or transfer of securities back to the company at price $ 85.00 per share. | 01 Sep 2026 | 6,400 | 5,925 (0%) | 0% | 85 | 544,000 | Common Stock |
| Structure Therapeutics Inc (ADR) | Xichen Lin | CHIEF SCIENTIFIC OFFICER | 01 Sep 2026 | 5,939 | 5,939 | - | - | American Depositary Shares | ||
| Crinetics Pharma Inc | Matthew K. Fust | Director | Sale or transfer of securities back to the company at price $ 85.00 per share. | 01 Sep 2026 | 5,925 | 0 (0%) | 0% | 85 | 503,625 | Common Stock |
| Crinetics Pharma Inc | Wendell D. Wierenga | Director | Sale or transfer of securities back to the company at price $ 85.00 per share. | 01 Sep 2026 | 5,925 | 0 (0%) | 0% | 85 | 503,625 | Common Stock |
| Crinetics Pharma Inc | Camille L. Bedrosian | Director | Sale or transfer of securities back to the company at price $ 85.00 per share. | 01 Sep 2026 | 5,925 | 0 (0%) | 0% | 85 | 503,625 | Common Stock |
| Crinetics Pharma Inc | Rogerio Vivaldi Coelho | Director | Sale or transfer of securities back to the company at price $ 85.00 per share. | 01 Sep 2026 | 5,925 | 0 (0%) | 0% | 85 | 503,625 | Common Stock |
| Crinetics Pharma Inc | Stephanie S. Okey | Director | Sale or transfer of securities back to the company at price $ 85.00 per share. | 01 Sep 2026 | 5,925 | 0 (0%) | 0% | 85 | 503,625 | Common Stock |
| Crinetics Pharma Inc | Weston Nichols | Director | Sale or transfer of securities back to the company at price $ 85.00 per share. | 01 Sep 2026 | 5,925 | 0 (0%) | 0% | 85 | 503,625 | Common Stock |
| Crinetics Pharma Inc | Caren Deardorf | Director | Sale or transfer of securities back to the company at price $ 85.00 per share. | 01 Sep 2026 | 5,925 | 0 (0%) | 0% | 85 | 503,625 | Common Stock |
| Edesa Biotech Inc | Pardeep Nijhawan | Director, Chief Executive Officer, Ten Percent Owner | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Sep 2026 | 5,714 | 899,100 (10%) | 0% | 0 | Common Shares | |
| Gilead Sciences | Daniel P. O'Day | Director, Chairman & CEO | Sale of securities on an exchange or to another person at price $ 149.38 per share. | 01 Sep 2026 | 5,408 | 577,133 (0%) | 0% | 149.4 | 807,856 | Common Stock |
| Alkermes PLC | Craig C. Hopkinson | EVP R&D, Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Sep 2026 | 5,000 | 61,276 | - | - | Employee Stock Option (Right to Buy) | |
| Alkermes PLC | Craig C. Hopkinson | EVP R&D, Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 24.59 per share. | 01 Sep 2026 | 5,000 | 74,389 (0%) | 0% | 24.6 | 122,950 | Ordinary Shares |
| Cytokinetics Inc | B. Lynne Parshall | Director | Sale of securities on an exchange or to another person at price $ 71.48 per share. | 01 Sep 2026 | 5,000 | 10,784 (0%) | 0% | 71.5 | 357,400 | Common Stock |
| Xeris Biopharma Holdings Inc | Steven M. Pieper | See Remarks | Sale of securities on an exchange or to another person at price $ 8.50 per share. | 01 Sep 2026 | 5,000 | 1,356,053 (4%) | 0% | 8.5 | 42,500 | Common Stock |
| Oruka Therapeutics Inc | Laura Lee Sandler | Chief Operating Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Sep 2026 | 5,000 | 74,996 | - | - | Employee Warrant (right to buy) | |
| Oruka Therapeutics Inc | Laura Lee Sandler | Chief Operating Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 7.80 per share. | 01 Sep 2026 | 5,000 | 241,384 | - | 7.8 | 39,000 | Common Stock |
| Oruka Therapeutics Inc | Lawrence Otto Klein | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 92.44 per share. | 01 Sep 2026 | 4,800 | 925,580 | - | 92.4 | 443,691 | Common Stock |
| Structure Therapeutics Inc (ADR) | Xichen Lin | CHIEF SCIENTIFIC OFFICER | Sale of securities on an exchange or to another person at price $ 0.00 per share. | 01 Sep 2026 | 4,539 | 100 | - | - | American Depositary Shares | |
| Crinetics Pharma Inc | Caren Deardorf | Director | Sale or transfer of securities back to the company at price $ 0.00 per share. | 01 Sep 2026 | 4,375 | 0 | - | - | Stock Option (Right to Buy) | |
| Oruka Therapeutics Inc | Laura Lee Sandler | Chief Operating Officer | Sale of securities on an exchange or to another person at price $ 92.01 per share. | 01 Sep 2026 | 4,000 | 236,384 | - | 92.0 | 368,054 | Common Stock |
| United Therapeutics Corp | Martine A. Rothblatt | Director, Chairperson & CEO | Sale of securities on an exchange or to another person at price $ 514.09 per share. | 01 Sep 2026 | 3,454 | 327,612 (0%) | 0% | 514.1 | 1,775,676 | Common Stock |
| AN2 Therapeutics Inc | Margaret M. FitzPatrick | Director | Purchase of securities on an exchange or from another person at price $ 5.53 per share. | 01 Sep 2026 | 2,098 | 10,708 | - | 5.5 | 11,602 | Common Stock |
| Crinetics Pharma Inc | Matthew K. Fust | Director | Sale or transfer of securities back to the company at price $ 0.00 per share. | 01 Sep 2026 | 2,092 | 0 | - | - | Stock Option (Right to Buy) | |
| United Therapeutics Corp | Martine A. Rothblatt | Director, Chairperson & CEO | Sale of securities on an exchange or to another person at price $ 513.12 per share. | 01 Sep 2026 | 1,732 | 331,066 (0%) | 0% | 513.1 | 888,721 | Common Stock |
| Crinetics Pharma Inc | Isabel Kalofonos | Chief Commercial Officer | Sale or transfer of securities back to the company at price $ 85.00 per share. | 01 Sep 2026 | 1,669 | 34,000 (0%) | 0% | 85 | 141,865 | Common Stock |
| MiNK Therapeutics Inc | Brian J. Corvese | Director | Grant, award, or other acquisition of securities at price $ 10.95 per share. | 01 Sep 2026 | 1,633 | 54,770 | - | 10.9 | 17,881 | Common Stock |
| MiNK Therapeutics Inc | Barbara Ryan | Director | Grant, award, or other acquisition of securities at price $ 10.95 per share. | 01 Sep 2026 | 1,622 | 23,591 | - | 11.0 | 17,761 | Common Stock |
| United Therapeutics Corp | Martine A. Rothblatt | Director, Chairperson & CEO | Sale of securities on an exchange or to another person at price $ 514.98 per share. | 01 Sep 2026 | 1,620 | 325,992 (0%) | 0% | 515.0 | 834,272 | Common Stock |
| Gilead Sciences | Daniel P. O'Day | Director, Chairman & CEO | Sale of securities on an exchange or to another person at price $ 147.51 per share. | 01 Sep 2026 | 1,600 | 590,533 (0%) | 0% | 147.5 | 236,014 | Common Stock |
| MiNK Therapeutics Inc | Peter Behner | Director | Grant, award, or other acquisition of securities at price $ 10.95 per share. | 01 Sep 2026 | 1,485 | 24,404 | - | 11.0 | 16,261 | Common Stock |
| United Therapeutics Corp | Martine A. Rothblatt | Director, Chairperson & CEO | Sale of securities on an exchange or to another person at price $ 516.03 per share. | 01 Sep 2026 | 1,469 | 324,523 (0%) | 0% | 516.0 | 758,049 | Common Stock |
| Nurix Therapeutics Inc | Gwenn Hansen | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Sep 2026 | 1,452 | 60,858 | - | - | Employee Stock Option (right to buy) | |
| Nurix Therapeutics Inc | Gwenn Hansen | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 1.86 per share. | 01 Sep 2026 | 1,452 | 118,679 | - | 1.9 | 2,701 | Common Stock |
| Nurix Therapeutics Inc | Gwenn Hansen | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 25.47 per share. | 01 Sep 2026 | 1,452 | 117,227 | - | 25.5 | 36,982 | Common Stock |
| Structure Therapeutics Inc (ADR) | Xichen Lin | CHIEF SCIENTIFIC OFFICER | Sale of securities on an exchange or to another person at price $ 0.00 per share. | 01 Sep 2026 | 1,300 | 4,639 | - | - | American Depositary Shares | |
| MiNK Therapeutics Inc | Ulf Wiinberg | Director | Grant, award, or other acquisition of securities at price $ 10.95 per share. | 01 Sep 2026 | 1,279 | 23,929 | - | 10.9 | 14,005 | Common Stock |
| MiNK Therapeutics Inc | John Holcomb | Director | Grant, award, or other acquisition of securities at price $ 10.95 per share. | 01 Sep 2026 | 1,233 | 4,691 | - | 10.9 | 13,501 | Common Stock |
| Crinetics Pharma Inc | R. Scott Struthers | Director, President & CEO | Sale or transfer of securities back to the company at price $ 85.00 per share. | 01 Sep 2026 | 1,000 | 0 (0%) | 0% | 85 | 85,000 | Common Stock |
| Oruka Therapeutics Inc | Laura Lee Sandler | Chief Operating Officer | Sale of securities on an exchange or to another person at price $ 91.05 per share. | 01 Sep 2026 | 1,000 | 240,384 | - | 91.0 | 91,048 | Common Stock |
| United Therapeutics Corp | Martine A. Rothblatt | Director, Chairperson & CEO | Sale of securities on an exchange or to another person at price $ 511.95 per share. | 01 Sep 2026 | 825 | 332,798 (0%) | 0% | 512.0 | 422,359 | Common Stock |
| United Therapeutics Corp | Martine A. Rothblatt | Director, Chairperson & CEO | Sale of securities on an exchange or to another person at price $ 510.72 per share. | 01 Sep 2026 | 320 | 333,623 (0%) | 0% | 510.7 | 163,432 | Common Stock |
| Structure Therapeutics Inc (ADR) | Xichen Lin | CHIEF SCIENTIFIC OFFICER | Sale of securities on an exchange or to another person at price $ 0.00 per share. | 01 Sep 2026 | 100 | 0 | - | - | American Depositary Shares | |
| United Therapeutics Corp | Martine A. Rothblatt | Director, Chairperson & CEO | Sale of securities on an exchange or to another person at price $ 516.62 per share. | 01 Sep 2026 | 80 | 324,443 (0%) | 0% | 516.6 | 41,330 | Common Stock |
| Karyopharm Therapeutics Inc | Kristin Abate | Chief Accounting Officer | Sale of securities on an exchange or to another person at price $ 2.00 per share. | 01 Sep 2026 | 19 | 23,782 (0%) | 0% | 2 | 38 | Common Stock |
| Acrivon Therapeutics Inc | Michaela Levin | Chief Business Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Aug 2026 | 130,000 | 130,000 | - | - | Stock Option (Right to Buy) | |
| Eterna Therapeutics Inc | Sanjeev Luther | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Aug 2026 | 118,848 | 118,848 | - | - | Stock Option (right to buy) | |
| Zoetis (Class A) | James K. Saccaro | EVP, CFO & COO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Aug 2026 | 81,063 | 81,063 | - | - | Restricted Stock Unit | |
| Rhythm Pharma Inc | Hunter C. Smith | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 25.79 per share. | 31 Aug 2026 | 57,187 | 176,798 (0%) | 0% | 25.8 | 1,474,853 | Common Stock |
| Rhythm Pharma Inc | Hunter C. Smith | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 31 Aug 2026 | 57,187 | 3,813 | - | - | Employee Stock Option (Right to Buy) | |
| Genelux Corp | Thomas Zindrick | President and CEO | Sale of securities on an exchange or to another person at price $ 2.67 per share. | 31 Aug 2026 | 34,463 | 1,226,427 | - | 2.7 | 91,899 | Common Stock |
| Decoy Therapeutics Inc | Frederick Pierce | Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Aug 2026 | 33,455 | 34,844 (0%) | 0% | 0 | Common Stock | |
| Acrivon Therapeutics Inc | Michaela Levin | Chief Business Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Aug 2026 | 30,000 | 30,000 | - | 0 | Common Stock | |
| Rhythm Pharma Inc | Hunter C. Smith | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 106.20 per share. | 31 Aug 2026 | 28,188 | 114,024 (0%) | 0% | 106.2 | 2,993,647 | Common Stock |
| Revolution Medicines Inc | Lorence H. Kim | Director | Sale of securities on an exchange or to another person at price $ 203.55 per share. | 31 Aug 2026 | 26,160 | 27,114 (0%) | 0% | 203.5 | 5,324,824 | Common Stock |
| Amylyx Pharma Inc | Karen Firestone | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 1.76 per share. | 31 Aug 2026 | 25,000 | 91,900 | - | 1.8 | 44,000 | Common Stock |
| Amylyx Pharma Inc | Karen Firestone | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 31 Aug 2026 | 25,000 | 0 | - | - | Stock Option (right to buy) | |
| Amylyx Pharma Inc | Karen Firestone | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 31 Aug 2026 | 25,000 | 0 | - | - | Stock Option (right to buy) | |
| Amylyx Pharma Inc | Karen Firestone | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 5.05 per share. | 31 Aug 2026 | 25,000 | 116,900 | - | 5.1 | 126,250 | Common Stock |
| Rhythm Pharma Inc | Hunter C. Smith | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 104.59 per share. | 31 Aug 2026 | 23,072 | 153,726 (0%) | 0% | 104.6 | 2,413,034 | Common Stock |
| Elicio Therapeutics Inc | Julian Adams | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Aug 2026 | 21,750 | 21,750 | - | - | Stock Option (Right to Buy) | |
| Elicio Therapeutics Inc | Robert R. Ruffolo | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Aug 2026 | 21,750 | 21,750 | - | - | Stock Option (Right to Buy) | |
| Elicio Therapeutics Inc | Karen J. Wilson | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Aug 2026 | 21,750 | 21,750 | - | - | Stock Option (Right to Buy) | |
| Elicio Therapeutics Inc | Allen R. Nissenson | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Aug 2026 | 21,750 | 21,750 | - | - | Stock Option (Right to Buy) | |
| Elicio Therapeutics Inc | Jay R. Venkatesan | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Aug 2026 | 21,750 | 21,750 | - | - | Stock Option (Right to Buy) | |
| Elicio Therapeutics Inc | Carol Gail Ashe | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Aug 2026 | 21,750 | 21,750 | - | - | Stock Option (Right to Buy) | |
| Elicio Therapeutics Inc | Yekaterina Chudnovsky | Director, Ten Percent Owner | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Aug 2026 | 21,750 | 21,750 | - | - | Stock Option (Right to Buy) | |
| Revolution Medicines Inc | Lorence H. Kim | Director | Sale of securities on an exchange or to another person at price $ 202.48 per share. | 31 Aug 2026 | 12,919 | 53,274 (0%) | 0% | 202.5 | 2,615,864 | Common Stock |
| Adaptive biotech Corp | Einterz Owen Katey | Director | Gift of securities by or to the insider at price $ 0.00 per share. | 31 Aug 2026 | 12,539 | 66,100 (0%) | 0% | - | Common Stock | |
| Fennec Pharma Inc | Pierre S. Sayad | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 12.18 per share. | 31 Aug 2026 | 12,000 | 9,519 (0%) | 0% | 12.2 | 146,160 | Common Shares |
| Rhythm Pharma Inc | Hunter C. Smith | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 105.37 per share. | 31 Aug 2026 | 11,514 | 142,212 (0%) | 0% | 105.4 | 1,213,232 | Common Stock |
| Genelux Corp | Joseph Cappello | Chief Technical Officer | Sale of securities on an exchange or to another person at price $ 2.74 per share. | 31 Aug 2026 | 10,257 | 318,480 | - | 2.7 | 28,112 | Common Stock |
| Cytokinetics Inc | Andrew M. Callos | EVP, Chief Commercial Officer | Sale of securities on an exchange or to another person at price $ 70.24 per share. | 31 Aug 2026 | 10,000 | 58,555 (0%) | 0% | 70.2 | 702,400 | Common Stock |
| Cytokinetics Inc | Andrew M. Callos | EVP, Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 31 Aug 2026 | 10,000 | 0 | - | - | Non-Qualified Stock Option (Right to Buy) | |
| Cytokinetics Inc | Andrew M. Callos | EVP, Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 23.26 per share. | 31 Aug 2026 | 10,000 | 68,555 (0%) | 0% | 23.3 | 232,600 | Common Stock |
| Fennec Pharma Inc | Rostislav Raykov | Former Director | Sale of securities on an exchange or to another person at price $ 12.11 per share. | 31 Aug 2026 | 10,000 | 124,411 (0%) | 0% | 12.1 | 121,100 | Common shares |
| VivoSim Labs Inc | Tony Lialin | Chief Commercial Officer | Purchase of securities on an exchange or from another person at price $ 0.28 per share. | 31 Aug 2026 | 10,000 | 10,000 (0%) | 0% | 0.3 | 2,804 | Common Stock |
| Genelux Corp | Tony Yu | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 2.75 per share. | 31 Aug 2026 | 9,683 | 258,688 | - | 2.8 | 26,658 | Common Stock |
| Decoy Therapeutics Inc | Mark J. Rosenblum | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Aug 2026 | 9,682 | 11,363 (0%) | 0% | 0 | Common Stock |
This section tracks all disclosures required by the U.S. Securities and Exchange Commission (SEC) under the Securities Exchange Act of 1934, particularly those related to Section 16 and Rule 10b-5, which govern insider trading activities in the U.S. market. These disclosures are made by corporate insiders, including executives, officers, directors, significant employees, and large shareholders, who are buying and selling stock in their own companies. You can search and filter within these results. You can also sort the information by clicking on the column headers.